HOME >> BIOLOGY >> NEWS
Common therapy for HIV associated with cervical abnormality regression

Among women infected with human immunodeficiency virus (HIV), a combination of antiretroviral drugs that helps boost the immune system is associated with the regression of a type of cervical abnormality that can eventually lead to cancer, according to a study in the July 21 issue of the Journal of the National Cancer Institute.

HIV infection is associated with an increased risk of abnormalities in the cervix called squamous intraepithelial lesions (SIL). In healthy women, the low-grade form of this type of abnormality often disappears on its own without treatment. Also, women who are HIV-positive are at an increased risk of infection with human papillomavirus (HPV), which are known to cause cervical cancer and its precursor lesions.

Highly active antiretroviral therapy (HAART) is a combination of several antiretroviral drugs that reduces the number of HIV particles in the bloodstream and helps boost immune system function. However, it is unclear whether the boost in immune status afforded by HAART improves the regression rates of SIL.

Linda Ahdieh-Grant, Ph.D., of Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues analyzed data from the Women's Interagency HIV Study to examine the long-term effects of HAART on the regression of cervical SIL. Of the approximately 2,000 women who participated in the study, there were 312 women who had normal Pap smears at the time they entered the study and then, at some point during the 7 years of follow-up, were diagnosed with SIL.

The introduction of HAART was associated with a regression of SIL. Compared with women whose abnormality regressed, women whose lesions did not regress had more advanced HIV disease, including lower T-cell counts. Before women started HAART, the rate of disease regression was 0.0%; after HAART was introduced, the regression rate was 12.5%. However, the authors point out that the majority of the lesions in HIV-infected women, even among th
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
20-Jul-2004


Page: 1 2

Related biology news :

1. Common cold virus can cause polio in mice when injected into muscles
2. Common call for action on European Research Council (ERC)
3. Common chemicals morphing into potential toxins in Arctic
4. Common worm provides insights into salmonella virulence
5. Common virus may contribute to uncommon bone disease in children
6. Common airborne substance makes asthmatics more sensitive to house dust mites: study
7. Common genetic damages in non-dividing cells lead to the creation of mutant proteins
8. Common nutrients fed to pregnant mice altered their offsprings coat color
9. Common treatment for depression is safe and effective for Alzheimers patients
10. Common gene variant increases risk of atherosclerosis
11. Common thyroid cancer gene mutation found

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/6/2019)... ... 06, 2019 , ... NDA Partners Chairman Carl Peck, ... with expertise in clinical pharmacology and pharmacometrics and a widely recognized expert in ... joined the firm as an Expert Consultant. , Dr. Stanski has served in ...
(Date:11/6/2019)... ... November 06, 2019 , ... Genomenon® announced ... now includes the ability to search the entirety of the genomic literature by ... and rare diseases. , Patients, particularly those with rare diseases, don’t always have ...
(Date:11/5/2019)... Seattle, WA (PRWEB) , ... November 05, 2019 ... ... LeCuyer & Amato Dentistry, providing state-of-the-art cosmetic and restorative dentistry to Seattle, WA, ... Receiving her Doctor of Dental Surgery degree from the University of Washington, Dr. ...
Breaking Biology News(10 mins):
(Date:11/19/2019)... ... 2019 , ... Supercomputing Conference – Cirrascale Cloud Services® ... Autonomous Vehicle , Medical Imaging, and Natural Language Processing (NLP) workflows, today announced ... software stack as part of its bare-metal cloud service offerings. In addition to ...
(Date:11/12/2019)... ... 12, 2019 , ... Peggy Lillis Foundation (PLF) has launched ... infection C. diff. The campaign, “See C. diff,” combines basic facts ... 30,000 people in the U.S. each year. The campaign also features a portrait ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. By ... the Fusion Bx 2.0 will give urologists across Europe the ability to perform ...
(Date:10/30/2019)... ... October 30, 2019 , ... While using cold plasma to kill cancer cells ... Dakota School of Mines & Technology are exploring new ways to regulate cold ... , If successful, the technique would prove to be a drug-free, minimally invasive cancer ...
Breaking Biology Technology:
Cached News: